SCHEMBL19001047

SCHEMBL19001047

C[C@@H]1CN(CCNc2ccc(C(C)(C)C)cc2)C[C@H](C)O1

nearest known ligand 0.60

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.60
EBP Q15125 2/20 0.51
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
NAMPT P43490 3/20 0.42
ALDH1A1 P00352 1/20 0.40
HSD17B10 Q99714 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
ADORA3 P0DMS8 1/20 0.40
CHRM1 P11229 1/20 0.40
DRD3 P35462 1/20 0.40
KCNH2 Q12809 1/20 0.40
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
USP2 O75604 1/20 0.38
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19000986 1.00 SIGMAR1 (0.60) SIGMAR1EBPCRHBPCRHR2NAMPT
SCHEMBL19012684 0.84 MAPT (0.48) SIGMAR1CRHBPCRHR2NAMPTALDH1A1
SCHEMBL19012694 0.84 MAPT (0.48) SIGMAR1CRHBPCRHR2NAMPTALDH1A1
SCHEMBL18436326 0.82 USP2 (0.46) NAMPTALDH1A1USP2GAA
SCHEMBL18436052 0.82 USP2 (0.46) NAMPTALDH1A1USP2GAA
SCHEMBL19012756 0.81 SIGMAR1 (0.45) SIGMAR1EBPNAMPTADORA3CHRM1
SCHEMBL17886710 0.79 NAMPT (0.60) SIGMAR1EBPCRHBPCRHR2NAMPT
SCHEMBL25040036 0.77 KDM4E (0.54) SIGMAR1ALDH1A1HRH3GAA
SCHEMBL13034201 0.77 SIGMAR1 (0.58) SIGMAR1
SCHEMBL11099523 0.74 SIGMAR1 (0.68) SIGMAR1EBPADORA3CHRM1DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-9938292-B2 Quinoline derivatives as SMO inhibitors GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-04-10 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174703-A1 QUINOLINE DERIVATIVES AS SMO INHIBITORS SMO, GLI1, SHH SIGMAR1 3478/4885EBP 2376/4885CRHBP 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.